Market research
COH.AU Cochlear Limited
AU AUD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 10B
- P/E ratio
- 65.25
- Analyst target
- 136.3415
- Dividend yield
- 2.5%
- Beta
- 0.24
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- AU000000COH5
- Market cap
- 10B
- P/E ratio
- 65.25
- Analyst target
- 136.3415
- Dividend yield
- 2.5%
- Beta
- 0.24
About
About Cochlear Limited
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers cochlear implant systems; replacement sound processors, accessories, and other services; bone conduction systems and replacement sound processors; and recipient support tools. The company also provides Cochlear connected care solutions, such as Cochlear Nucleus SmartNav System; Cochlear Custom Sound Pro Fitting Software; Cochlear Remote Assist; Cochlear Remote Check; and Cochlear Link. It offers its products and services under the Cochlear, Nucleus, Nexa, Osia, and Cochlear Baha brands. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
Research context
Cochlear Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the COH.AU discussion.
5 years, 6 months ago
Cochlear Limited is currently in a long term uptrend where the price is trading 14.0% above its 200 day moving average.
From a valuation standpoint, the stock is 96.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.4.
Cochlear Limited's total revenue sank by 1.7% to $743M since the same quarter in the previous year.
Its net income has increased by 49.8% to $236M since the same quarter in the previous year.
Finally, its free cash flow grew by 1119.6% to $34M since the same quarter in the previous year.
Based on the above factors, Cochlear Limited gets an overall score of 4/5.